# Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19

> **NCT04362189** · PHASE2 · TERMINATED · sponsor: **Hope Biosciences Research Foundation** · enrollment: 48 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** HB-adMSC
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04362189
- **Lead sponsor:** Hope Biosciences Research Foundation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-30
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** No need to continue with the availability of the COVID-19 VACCINE
- **Last updated:** 2025-09-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04362189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04362189, "Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04362189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*